2021
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute undifferentiated leukemiaWhite blood cellsLymphoblastic leukemiaAcute leukemiaBone Marrow Pathology GroupHigher white blood cellEvent-free survivalNatural killer cellsClinical outcome dataNative immune systemMore frequent expressionAUL patientsFree survivalAmbiguous lineageOverall survivalCytoplasmic CD3Leukemia groupClinical presentationHLA-DRKiller cellsPlatelet countProvisional entityCD10 expressionMyeloid leukemia
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma